Here’s What Analysts Think About ADMA Biologics (ADMA)

ADMA Biologics, Inc. (NASDAQ:ADMA) is one of the best small cap stocks to buy for 10x potential. On May 7, Mizuho lowered the price target on ADMA Biologics, Inc. (NASDAQ:ADMA) to $20 from $24 while maintaining an Outperform rating on the shares. The stock also received a rating update from Canaccord the same day, with the firm cutting the price target on the stock to $18 from $21 while maintaining a Buy rating on the shares. It stated that fiscal Q1 2026 was a reset quarter for ADMA Biologics, Inc. (NASDAQ:ADMA), with results falling short and guidance lowered primarily because of pressure on Bivigam within the standard IG market. It also stated that the key product and value driver, Asceniv, held up pretty well in the quarter.

ADMA Biologics (ADMA) Drops 14.7% W/W as 3 Execs Unload Portfolios

In its financial results for fiscal Q1 2026 released on May 6, ADMA Biologics, Inc. (NASDAQ:ADMA) reported total revenue of $114.5 million, flat year-over-year, with ASCENIV revenue growing 28% year-over-year and BIVIGAM revenue dropping 54% year-over-year.

ADMA Biologics, Inc. (NASDAQ:ADMA) is a biopharmaceutical company that manufactures, markets, and develops speciality plasma-derived biologics. It conducts operations through the following business segments: ADMA BioManufacturing and Plasma Collection Center.

While we acknowledge the risk and potential of ADMA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ADMA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 1759070 - 1